Literature DB >> 11882361

The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation.

Ronald J Hill1, Sergey Zozulya, Ying-Lin Lu, Kevin Ward, Mikhail Gishizky, Bahija Jallal.   

Abstract

OBJECTIVE: Following activation of T cells, phosphorylation of tyrosine residues occurs through a complex signaling process involving protein tyrosine kinases, phosphatases, and a variety of adapter molecules including Grb2. We have attempted to identify new signaling molecules that are important for the activation response.
METHODS: Using a protein interaction screening protocol based on phage display, T-cell signaling components that associate with the adapter molecule, Grb2, the lymphoid-specific tyrosine phosphatase Lyp was identified. Using transcriptional reporter assays, the role of Lyp in T-cell activation was studied by overexpression of wild-type or catalytically inactive mutants of Lyp.
RESULTS: A GST fusion containing the C-terminal SH3 domain of Grb2 bound to the nucleotide exchange factor Sos or Grb2-associated binder 2 (Gab2). In contrast, the N-terminal SH3-containing fusion bound to the protein tyrosine phosphatase Lyp. Grb2 was co-immunoprecipitated with Lyp in 293T cells overexpressing both proteins. Using Northern blot analysis, Lyp was found to be expressed predominantly in hematopoietic tissue, including spleen, lymph node, thymus, peripheral blood leukocytes, bone marrow, and fetal liver. Two human T-cell lines, Jurkat and HuT78, expressed both Lyp mRNA and protein. Overexpression of wild-type Lyp or a catalytically inactive, substrate-trapping mutant (D195A) in Jurkat cells inhibited transcriptional activity initiated by anti-CD3 and anti-CD28 antibodies. In contrast, two other catalytically inactive mutants (R233M or C227S) had no effect.
CONCLUSION: These data demonstrate a novel interaction between the phosphatase Lyp and the adaptor Grb2 and are consistent with a negative regulatory role for Lyp in T-cell signaling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882361     DOI: 10.1016/s0301-472x(01)00794-9

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  34 in total

1.  Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue.

Authors:  Edoardo Fiorillo; Valeria Orrú; Stephanie M Stanford; Yingge Liu; Mogjiborahman Salek; Novella Rapini; Aaron D Schenone; Patrizia Saccucci; Lucia G Delogu; Federica Angelini; Maria Luisa Manca Bitti; Christian Schmedt; Andrew C Chan; Oreste Acuto; Nunzio Bottini
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

Review 3.  The Contribution of PTPN22 to Rheumatic Disease.

Authors:  Tomas Mustelin; Nunzio Bottini; Stephanie M Stanford
Journal:  Arthritis Rheumatol       Date:  2019-03-02       Impact factor: 10.995

4.  Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.

Authors:  A Blasetti; C Di Giulio; S Tumini; M Provenzano; D Rapino; L Comegna; G Prezioso; R Chiuri; S Franchini; F Chiarelli; L Stuppia
Journal:  Pharmacogenomics J       Date:  2016-02-23       Impact factor: 3.550

Review 5.  Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases.

Authors:  Stephanie M Stanford; Tomas M Mustelin; Nunzio Bottini
Journal:  Semin Immunopathol       Date:  2010-03-04       Impact factor: 9.623

6.  Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis.

Authors:  Hui-Hsin Chang; Ching-Huang Ho; Beverly Tomita; Andrea A Silva; Jeffrey A Sparks; Elizabeth W Karlson; Deepak A Rao; Yvonne C Lee; I-Cheng Ho
Journal:  J Autoimmun       Date:  2019-04-26       Impact factor: 7.094

7.  Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis.

Authors:  Chun-Huang Huang; James Cheng-Chung Wei; Chun-Chieh Chen; Chih-Shien Chuang; Chia-Hsuan Chou; Yu-Jie Lin; Ming-Fuu Wang; Ruey-Hong Wong
Journal:  Rheumatol Int       Date:  2013-11-09       Impact factor: 2.631

8.  Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis.

Authors:  F B S Briggs; P P Ramsay; E Madden; J M Norris; V M Holers; T R Mikuls; T Sokka; M F Seldin; P K Gregersen; L A Criswell; L F Barcellos
Journal:  Genes Immun       Date:  2010-01-21       Impact factor: 2.676

9.  Overexpression of GRB2 is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Li-Yan Li; En-Min Li; Zhi-Yong Wu; Hui-Hui Cao; Jin-Hui Shen; Xiu-E Xu; Bo Chen; Jian-Yi Wu; Li-Yan Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

10.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.

Authors:  Ann B Begovich; Victoria E H Carlton; Lee A Honigberg; Steven J Schrodi; Anand P Chokkalingam; Heather C Alexander; Kristin G Ardlie; Qiqing Huang; Ashley M Smith; Jill M Spoerke; Marion T Conn; Monica Chang; Sheng-Yung P Chang; Randall K Saiki; Joseph J Catanese; Diane U Leong; Veronica E Garcia; Linda B McAllister; Douglas A Jeffery; Annette T Lee; Franak Batliwalla; Elaine Remmers; Lindsey A Criswell; Michael F Seldin; Daniel L Kastner; Christopher I Amos; John J Sninsky; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.